A brief overview of the advanced urothelial carcinoma landscape encompassing disease course and standard of care treatment strategies.

Expert perspectives on optimal treatment approaches in patients with newly diagnosed metastatic urothelial carcinoma.

The overall impact that maintenance therapy has had on patient outcomes in advanced or metastatic urothelial carcinoma.

A review of the JAVELIN Bladder 100 trial, which evaluated avelumab maintenance therapy following frontline chemotherapy in metastatic urothelial carcinoma.

Practical advice on maintenance therapy in metastatic urothelial carcinoma, covering patient education, duration of therapy, and clinical guidelines.

Expert perspectives on novel treatment approaches being investigated in the second-line setting of metastatic urothelial carcinoma and beyond.

Clinical pearls of advice regarding the optimal management of metastatic urothelial carcinoma in today’s treatment landscape.

Expert perspective on the current treatment paradigm of metastatic urothelial carcinoma across different regions of the world.

Considerations for the role of immunotherapy in metastatic urothelial carcinoma as maintenance or switch therapy.

Ignacio Duran, MD, PhD, reflects on the JAVELIN Bladder 100 trial, which analyzed avelumab as frontline maintenance therapy in metastatic urothelial carcinoma.

Shared insight on the use of maintenance therapy in metastatic urothelial carcinoma with regard to PD-L1 testing and patient education.

Following frontline maintenance therapy in metastatic urothelial carcinoma, Ignacio Duran, MD, PhD, considers optimal second-line treatment options.

Expert reflection on the current unmet needs in metastatic urothelial carcinoma and hope for future improvements in the treatment armamentarium.